CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-21 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +5,161,290 | $7.75 | $40.0M | 13,043,179 |
| 2021-07-06 | Manning Paul B 10% owner | Purchase | +312,500 | $16.00 | $5.0M | 3,352,693 |
| 2021-07-06 | Stalfort John A III Director | Purchase | +35,000 | $16.00 | $560K | 172,324 |
| 2021-07-06 | Hardie Robert D. 10% owner | Purchase | +312,500 | $16.00 | $5.0M | 3,352,693 |
| 2021-07-06 | Hardie Robert D. 10% owner | Purchase | +750,000 | $16.00 | $12.0M | 3,951,156 |
| 2021-07-06 | Fountain Nathan B Director | Purchase | +6,250 | $16.00 | $100K | 6,250 |
| 2021-07-06 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +1,759,332 | $16.00 | $28.1M | 7,881,889 |
| 2021-07-06 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +115,668 | $16.00 | $1.9M | 1,300,034 |
| 2021-07-06 | Sands Capital Ventures Discovery Fund III, L.P. 10% owner | Purchase | +450,000 | $14.88 | $6.7M | 3,417,075 |
Page 1 of 1 · 9 trades